Put Options

6 transactions
Quarter Operation Price Per put puts change puts Held SEC Form
Q4 2023

Feb 14, 2024

BUY
$41.99 - $62.38 $19 Million - $28.2 Million
452,700 New
452,700 $26.6 Million
Q3 2022

Nov 14, 2022

BUY
$59.5 - $86.7 $119,000 - $173,400
2,000 Added 71.43%
4,800 $335,000
Q2 2022

Aug 15, 2022

BUY
$39.16 - $88.71 $109,647 - $248,387
2,800 New
2,800 $188,000
Q4 2021

Feb 14, 2022

SELL
$132.01 - $190.29 $514,838 - $742,131
-3,900 Closed
0 $0
Q3 2021

Nov 15, 2021

BUY
$132.13 - $177.45 $462,455 - $621,075
3,500 Added 875.0%
3,900 $690,000
Q1 2021

May 17, 2021

BUY
$158.92 - $221.61 $63,567 - $88,644
400 New
400 $69,000

Others Institutions Holding MRTX

About Mirati Therapeutics, Inc.


  • Ticker MRTX
  • Exchange NASDAQ
  • Sector Healthcare
  • Industry Biotechnology
  • Shares Outstandng 55,609,800
  • Description
  • Mirati Therapeutics, Inc., a clinical-stage oncology company, develops product candidates to address the genetic and immunological promoters of cancer in the United States. The company develops MRTX849, a KRAS G12C inhibitor, which is in Phase 1/2 clinical trial for treating non-small cell lung (NSCL), colorectal, pancreatic, and other cancers; ...
More about MRTX
Track This Portfolio

Track Css LLC Portfolio

Follow Css LLC and customize your updates to receive the information that matters most to you.

Portfolio Update

Get notified when there are updates to the investment portfolio of Css LLC, based on Form 13F filings with the SEC.

News

Stay updated on Css LLC with notifications on news.